Arduino Research Highlights Advances in HIV Treatment

Roberto C. Arduino, MD, professor in the Division of Infectious Diseases at McGovern Medical School at UTHealth Houston, has contributed to several recent studies advancing the understanding and treatment of HIV.

Arduino, an expert in HIV care and clinical research, leads the NIH-funded Houston AIDS Research Team and is actively involved in clinical studies focused on antiretroviral therapies, treatment strategies, immune activation and inflammation, and approaches toward HIV remission and cure.

Pharmacogenetics and HIV Treatment

Arduino contributed to research examining genetic factors associated with plasma concentrations of dolutegravir among people with HIV receiving a one-month regimen of rifapentine and isoniazid for latent tuberculosis infection.

Read the publication: Pharmacogenetics of Plasma Dolutegravir Exposure During 1-Month Rifapentine/Isoniazid Treatment of Latent Tuberculosis (external link) on PubMed.

Broadly Neutralizing Antibodies for HIV-1

Arduino also contributed to a phase 1/2a clinical trial evaluating the safety and antiviral effects of a combination of three broadly neutralizing antibodies targeting HIV-1.

Read the publication: Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial (external link) on PubMed.

Antiretroviral Therapy During Early HIV Infection

Additional research involving Arduino examined the virologic and immunologic outcomes associated with initiating antiretroviral therapy during acute or early HIV infection.

Read the publication: Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes (external link) on PubMed.

---